Thrivent Small Cap Growth Fund Q2 2026: Key Holdings and Investor Takeaways

Thrivent's Small Cap Growth Fund published its review for the second quarter of 2026, offering a window into the fund's strategy during a period of market volatility. The fund managers adjusted positions to capitalize on emerging opportunities in technology and healthcare, sectors that have shown resilience despite broader economic uncertainty. Top holdings included companies with strong earnings momentum and innovative product pipelines.

Among the notable changes, the fund increased exposure to software and biotech firms, betting on continued demand for digital transformation and medical advancements. Conversely, it trimmed positions in consumer discretionary stocks, reflecting caution about weakening consumer spending. The portfolio shift suggests a focus on high-growth areas with durable competitive advantages.

For individual investors, the fund's moves signal that small-cap growth remains attractive but requires selectivity. Companies with solid balance sheets and clear catalysts are preferred over speculative plays. The review also noted that valuations in small-cap growth have become more reasonable after the recent correction, presenting potential entry points.

In terms of performance, the fund outperformed its benchmark during the quarter, driven by stock picks in the technology sector. However, managers warned that inflation and interest rate policies remain key risks. They emphasized a disciplined approach to risk management and maintaining liquidity for tactical opportunities.

The Q2 review underscores the importance of active management in small-cap investing. Investors should monitor sector rotations and economic data to align their portfolios with the fund's strategies. Thrivent's focus on quality growth stocks offers a blueprint for navigating uncertain markets.